SRC and neuroblastoma: In mock cells, Src activity was highly sensitive to two well-known Src inhibitor, saracatinib (which also inhibit the Abl kinase [43]) at 100 nM, and sugen (used in preclinical NB models [44]) at 1 μM (Fig. 6a).